+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
ID07100210

Evaluating Safety and Activity of IL-22BPLNP Compound in Adults with Advanced Refractory Malignant Solid Tumors

Led by Xingchen Peng · Updated on 2025-12-29

6

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research aims to investigate the safety, tolerability, and preliminary anti-tumor activity of the IL-22BPLNP compound in patients with refractory malignant solid tumors. These tumors include advanced soft tissue sarcoma, advanced head and neck squamous cell carcinoma, and malignant melanoma. The study focuses on patients who have failed second-line treatments or have advanced recurrence or metastatic disease, addressing a serious health challenge with limited current treatment options. Participants will receive the IL-22BPLNP compound through intratumoral injections. Six patients are divided into two dose groups, receiving either 25 micrograms or 50 micrograms of the compound. The treatment involves five doses four weekly doses followed by a fifth dose one month after the fourth. This basic immunization phase lasts about two months, with personalized treatment following. During the study, participants will be closely monitored for safety and treatment response. Researchers will assess dose-limiting toxicities and interruptions due to adverse events. They will also measure tumor response rates, disease control, remission times, progression-free survival, and overall survival. The observation period for some outcomes extends up to 36 months, ensuring thorough evaluation of the compounds effects and safety throughout and after treatment.

CONDITIONS

Brief Title

A Clinical Trial Evaluating IL-22BP/LNP Compound in Refractory Malignant Solid Tumors for Safety, Tolerability and Activity

Research Team

X

Xingchen Peng

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here